2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1929

Timing Of Total Knee Arthroplasty: A Decision Analysis
Abstract Number: 2189

TLR 4 Endogenous Ligand MRP8/14 Levels in Enthesitis Related Arthritis (ERA) and Its Association With Disease Activity and TLR 4 Expression
Abstract Number: 342

TNF Blockage In Psoriatic Arthritis: Long-Term Effect On Lipid Profile
Abstract Number: 2202

TNF-α Is Associated With Cognitive Impairment In Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 2397

To Which Extent May The Familial Risk Of Rheumatoid Arthritis Be Explained By Established Risk Factors?
Abstract Number: 1313

Tobacco Exposure Is Associated With Radiographic Damage In Hispanic and African American Rheumatoid Arthritis Patients
Abstract Number: 2368

Tocilizumab Efficiently Halts Radiographic Progression In Patients With Rheumatoid Arthritis and Swollen Joint Counts Within a Year Predict Long-Term Radiographic Outcomes: Three Year Results From Michinoku Tocilizumab Study Group
Abstract Number: 2375

Tocilizumab Glucocorticoids Sparing Effect: The Spare-1 Study
Abstract Number: 1410

Tocilizumab Improves Left Ventricular Mass and Cardiac Output in Patients With Rheumatoid Arthritis. A Cohort Study
Abstract Number: 2767

Tocilizumab In Combination Therapy and Monotherapy Versus Methotrexate In Methotrexate-Naive Patients With Early Rheumatoid Arthritis: Clinical and Radiographic Outcomes From a Randomized, Placebo-Controlled Trial
Abstract Number: 2351

Tocilizumab In Patients With Rheumatoid Arthritis and Rates Of Malignancy: Results From Long-Term Extension Clinical Trials
Abstract Number: 1687

Tocilizumab In Refractory Aortitis: A Multicenter Study Of 13 Patients
Abstract Number: 1686

Tocilizumab In Refractory Takayasu Arteritis: a Case Series and Updated Literature Review.²
Abstract Number: 450

Tocilizumab Monotherapy Compared With Adalimumab Monotherapy In Patients With Rheumatoid Arthritis: An Evaluation Of High-Density Lipoprotein Composition
Abstract Number: 2389

Tocilizumab Survives Introducing The Hemadialysis Longer Than Oral Medicine In AA Amyloidosis Patients With Rheumatoid Arthritis Of Renal Insufficiency

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].